Poly-and oligodonal T cell stimuli like anti-CD3e monoclonal antibody or Staphylococcus aureus enterotoxin B (SEB), injected at doses that per se are not lethal, provoke acute death within less than 24 h, provided that endogenous glucocorticoids (GC) are depleted by adrenalectomy or by injection of saturating amounts of the GC receptor antagonist RU-38486 (mifepristone). Pharmacological doses of the GC agonist dexamethasone (DEX) alter the in vivo response of splenic V38 + T cells to SEB, thus impeding the expansion of such cells and causing their rapid (3 d) clonal deletion. In contrast, coadministration of RU-38486 counteracts a SEB-induced early (12 h) reduction of V38+CD4 + and V38+CD8 + spleen cells. In vivo T cell stimulation by injection of bacterial superantigen induces a rapid (peak at 90-120 rain) increase in corticosterone serum levels, suggesting that endogenous GC might control early T cell activation. Accordingly, kinetic studies revealed that RU-38486 has to be administered within 2 h after superantigen administration to exert its lethal effect. Similarly, exogenous GC must be injected during this critical phase (2 h) to rescue animals from acute death induced by coinjection of SEB and D-galactosamine (GAIN). Adrenalectomy, injection of RU-38486 and priming with GaIN per se provoke the programmed death of peripheral CD4 + and CD8 + T cells. Thus, three manipulations that sensitize mice for the lethal effect of T cell stimulation also exert a proapoptotic effect on peripheral T cells. In synthesis, endogenous and exogenous GC regulate T cell responses and determine the propensity of peripheral T cells to undergo apoptosis.
Summary
Poly-and oligodonal T cell stimuli like anti-CD3e monoclonal antibody or Staphylococcus aureus enterotoxin B (SEB), injected at doses that per se are not lethal, provoke acute death within less than 24 h, provided that endogenous glucocorticoids (GC) are depleted by adrenalectomy or by injection of saturating amounts of the GC receptor antagonist RU-38486 (mifepristone). Pharmacological doses of the GC agonist dexamethasone (DEX) alter the in vivo response of splenic V38 + T cells to SEB, thus impeding the expansion of such cells and causing their rapid (3 d) clonal deletion. In contrast, coadministration of RU-38486 counteracts a SEB-induced early (12 h) reduction of V38+CD4 + and V38+CD8 + spleen cells. In vivo T cell stimulation by injection of bacterial superantigen induces a rapid (peak at 90-120 rain) increase in corticosterone serum levels, suggesting that endogenous GC might control early T cell activation. Accordingly, kinetic studies revealed that RU-38486 has to be administered within 2 h after superantigen administration to exert its lethal effect. Similarly, exogenous GC must be injected during this critical phase (2 h) to rescue animals from acute death induced by coinjection of SEB and D-galactosamine (GAIN). Adrenalectomy, injection of RU-38486 and priming with GaIN per se provoke the programmed death of peripheral CD4 + and CD8 + T cells. Thus, three manipulations that sensitize mice for the lethal effect of T cell stimulation also exert a proapoptotic effect on peripheral T cells. In synthesis, endogenous and exogenous GC regulate T cell responses and determine the propensity of peripheral T cells to undergo apoptosis.
S
Ynthetic glucocorticoid (GC) 1 agonists are used for therapy of a broad spectrum of organ-specific and generalized autoimmune diseases. In the same way, endogenous GC secreted by the adrenal glands may act as immunosuppressive and antiinflammatory agents that contend lifethreatening overreactions of the immune system, as well as autoaggressive responses (for reviews see references 1, 2). GC inhibit macrophage functions, including cytotoxic functions, processing, and presentation of antigen to T cells, inhibit the production of IL-2 and IFN-3, in T lymphocytes (3), shift T cell responses from the Thl to the Th2 type (4), decrease the activity of NK cells, induce programmed cell death in a variety of different immunologically relevant cells, including immature T and B cell precursors (for reviews see references 5, 6) and mature T cells (7) , and inhibit the synthesis of a variety of proimflammatory cytokines (IL-1, IL-6, and TNF-o 0 (8) . Immune activation frequently is associated with an in-crease in ACTH and GC secretion, and the susceptibility of certain animal strains to develop autoimmune diseases is linked to a deficient GC-mediated inhibition of immune function (2, (9) (10) (11) (12) .
Recently, a synthetic steroid, KU-38486 (RU486, mifepristone), with potent antiprogestational and antiglucocorticoid activity has become available for clinical use as an abortifacient agent (13, 14) and for treatment of gestagen-dependent tumors and hypercortisolism (15) . In the present study, we investigated the effect of RU-38486 on T cell activation in vivo. It is shown that RU-38486, present during the acute phase of T cell stimulation, dramatically enhances the lethality of in vivo T cell activation. Evidence is presented that administration of T cell activators provokes an acute transient release of corticosterone (CN) into the circulation. Administration of GC reduces the toxicity of T cell activation, while preventing the antigen-driven expansion and accelerating the deletion of the specific T cell subset. The data presented in this report support the contention that (endogenous) GC intervene in the regulation of the activation, expansion, antigenspecific deletion, and programmed cell death of peripheral T cells in vivo.
Materials and Methods
Animals and In Vivo Treatment. Male Assessment ofApoptotic DNA Fragmentation. CD3 +, CD4 ÷ or CD8 ÷ splenic T cells were prepared by negative selection using columns (Cellect~'; Biotex, Edmonton, Canada). Contamination with slg ÷, CD8 +, or CD4 ÷ cells was <1% for CD3 ÷, CD4 +, and CD8 ÷ T cells, respectively. After a brief in vitro culture (2 h at 37°C in RPMI 1640 supplemented with 10% FCS), 2 x 106 cells were washed, pelleted, and incubated at 50% in 20 #1 of 10 mM EDTA, 50 mM Tris-HC1, 0.5% sodium laurylsarkosinate, and 0.5/zg/ml protease K, followed by the addition of 10 gl of 10/zg/ml RNase A, incubation for 1 h at 37°C, and electrophoresis over a 1.2% gel containing 0.1/xg/ml ethidium bromide, as described (20, 21).
Results and Discussion

Endogenous GC Protect Mice against the Lethal Effect of Acute T Cell Activation In Vivo.
Normal BALB/c mice do not succumb to doses as high as 250 gg of the CD3E-specific mAb 145-Cll, an antibody that induces a cytokine release syndrome via the nonspecific polyclonal stimulation oft cells (22) . However, two manipulations sensitize to the lethal effect of anti-CD3, namely coinjection of the monosaccharide GaIN (22) and coinjection of the GC antagonist RU-38486 (Table 1) , an agent that has been previously shown to sensitize mice to the lethal effect of TNF (23), one of the major intermediate effector molecules of polyclonal T cell stimulation (22, 24) . The ED50 of otCD3 combined with GaiN (*2.5 #g otCD3) is lower than that of otCD3 combined with RU-38486 (>10 /zg otCD3). The sensitizing effect of the anti-GC RU-38486 is abolished by coadministration of DEX and is not restricted to otCD3, but also concerns the superantigen SEB, which specifically stimulates Vj58 + T cells (about 30% of CD3 + T cells in BALB/c mice). The toxic effect of SEB requires the presence of large numbers of superantigen-reactive V/38 + T cells (25) . Accordingly, SEA (which stimulates V/33 + and V~ll + T cells) is not toxic for BALB/c mice that contain <1% of SEA-reactive V/33 + or V/811 + cells among peripheral lymphocytes (but kills GaiN-sensitized C57/B16 mice that contain >10% VB3 + plus V/311 + T cells). Surprisingly, the VB8-specific antibody F23.1 was not capable of killing GAIN-or RU-38486-sensitized BALB/c mice (Table 1) , indicating that the mode of stimulation exerted by this antibody must differ from that of the equally V~8-specific superantigen SEB. Accordingly, the signal transduction cascades triggered by superantigens and conventional stimuli exhibit an only partial overlap in vitro (26, 27) . Moreover, F23.1 differs from SEB in the sense that its in vitro application fails to trigger an expansion of V/% + T cells but rather provokes an immediate programmed cell death-mediated depletion of V/38 + T cells (data not shown).
Since pharmacological doses of RU-38486 might have GCagonistic and nonspecific toxic effects (28), we tested whether adrenalectomy also would predispose BALB/c mice to the lethal effect of SEB. Indeed, adrenalectomy with the subsequent decrease in endogenous GC level rendered animals susceptible to the acute lethal effect of SEB. This phenomenon was readily reverted by administration of low doses of DEX (Table 1) . Thus, endogenous GC control the acute response to T cell stimulation in vivo, and the effect of RU-38486 can be attributed to the blockade of GC receptors. Fig. 1 , the injection of SEB induces an increase in circulating CN levels by at least one order of magnitude over the baseline (peak at 90-120 rain). This increase in plasma CN drops off within 6 h after injection. PBS controls. After 2 h, animals were killed by cervical dislocation and heart blood was immediately removed. CN serum levels (three to four animals per group) were measured by KIA. was increased in the presence of RU-38486, but was completely prevented by pretreatment of animals with DEX (1 mg i.p. 2 h before the injection of SEB), suggesting the action of a GC-mediated feedback inhibition of the immunestimulated CN release (1, 29) . Injection of SEB into mice that had been primed 6 h earlier with SEB, a manipulation that leads to an exhaustion of T cell function and lymphokine release (30) To test whether the SEB-triggered short-term elevation of CN is relevant to the outcome of SEB responses in vivo, the GC antagonist RU-38486 and the GC superagonist DEX were injected at different intervals into mice challenged with SEB. RU-38486 only increased the susceptibility to the lethal effect of SEB when given within 2 h after SEB challenge. Application of RU-38486 after 4 h failed to provoke death (Fig. 2 A) . Along the same line, DEX only was effective in preventing the acute death of mice receiving simultaneous treatment with SEB and GAIN, when administered within 2 h (Fig. 2 B) . These observations suggest the physiological relevance of acute short-term elevations of GC in the regulation of the immune response.
Mutual Interaction between the Immune and the GC Systems during a Critical Phase of Several Hours. As shown in
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Effect of GC on Superantigen-induced Clonal Expansion and
Deletion of Peripheral T Cells. In vivo injection of SEB entails a phase of donas expansion of VB8 + T ceils (maximum, 2-3 d), followed by a phase of clonal deletion (minimum, 10 d). These changes affect both the CD4 + and the CD8 + subsets (20, 21, 31, 32) . To test the possible effect of endogenous GC on the SEB-driven sequential expansion and contraction of V/~8 + T cells, RU-38486 was administered to mice 4 h subsequent to the SEB challenge (as in Fig. 2) , followed by two daily injections of RU-38486 throughout the experiment. This should be suffident to reduce the effect of endogenous GC, as RU-38486 saturates the GC receptor within 1 h after in vivo administration and inhibits the transcription of GC-inducible genes for several hours (15, 33) . Moreover, the fact that this protocol of RU-38486 administration and surgical adrenalectomy have similar effects in other experimental systems (vide infra) suggests that the GC receptor blockade is rather complete. In spite of this manipulation, no significant changes in the SEB-modulated expression of . Alternatively, the frequency of V138 § T cells was assessed 12 h subsequent to SEB injection, and RU-38486 was injected once either together with SEB or 4 h later (B). In a further experiment, V~38 + T cells DEX (1 mg i.p.) was given 2 h before the injection of SEB and was repeated once 24 h later (C). PBS served as vehicle control for RU-38486 and DEX injections, respectively. Mean values _+ SEM for three to six animals are given. Data are representative for three independent experiments. after 2 d (Fig. 3 A) . This acute, transient, previously undescribed drop in V38+CD4 + and V38+CD8 + cells apparently is GC dependent, since it is fully abolished by coadministration of RU-38486. No such effects were observed when RU-38486 was given 4 h after SEB (Fig. 3 B) , thus underlining the probable role of the GC elevation over baseline levels that immediately follows SEB injection. High doses of exogenous GC present during the early phase of the SEB response provoke a major alteration in the behavior of the V38 + subset. Instead of exhibiting an expansion of VB8 + T cells, DEX-treated animals display a highly significant rapid deletion of V38 + T cells that can be well V38 among total T cells was detected as compared to vehicleinjected controls (Fig. 3 A) , indicating that baseline G C levels are not important for the regulation of clonal expansion and deletion.
Since RU-38486 coadministered with SEB is lethal within 24 h (Fig. 2 A) , it cannot be determined whether the G C peak after SEB injection (Fig. 1) is relevant to the regulation of SEB responses that become detectable several days after SEB. We therefore evaluated the consequences of SEB injection on the repertoire of splenic T cells within a shorter interval. 4-8 h after intravenous administration of SEB the percentage of VB8 + T cells begins to decline (data not shown) to reach significantly reduced levels after 12 h (Fig. 3 B) , i.e., before the expansion of V38 + cells that is well detectable (Fig. 3 B) . This in vivo finding contrasts with in vitro data that show that GC actually inhibit the CD3-stimulated activation cell death of T cell hybridomas (34) and thymocytes (35) . It remains to be determined whether these discrepancies are due to rather disparate experimental systems (in vivo versus in vitro) or must be attributed to the nature of the trigger targeted to the TCR (olCD3 versus superantigen). Although reminiscent of the effect of CsA, which also may enhance the SEB-driven deletion of VB8 + T cells (36) , DEX is much more efficient in this system, revealing its prodeletional effect after one single injection of SEB, whereas the effect of CsA is only observed after several rounds of SEB treatment (36) .
Withdrawal of Endogenous GC Induces Programmed Cell Death of Peripheral T Cells.
Shortly after treatment with RU-38486, the cellularity of the thymus and the spleen increases by up to 100%, reaching its maximum 48 h after the initiation of RU-38486 injections in 12-h intervals (Fig. 4 A) . Simultaneously, the oligonucleosomal DNA fragmentation pattern typical of programmed cell death becomes detectable among splenic T cells (Fig. 4 B) . Whereas vehicle controls do not show signs of apoptosis, peripheral T cells from RU-38486 treated mice display a DNA fragmentation that increases with the duration of RU-38486 exposure and is accompanied by a relative depletion of splenic T cells and thymocytes. DNA fragmentation was also observed in adrenalectomized mice. This phenomenon concerned both CD4 + and CD8 § T cells. Surprisingly, GaIN per se also induced PCD of purified CD3 + splenic T cells, (Fig. 4 B) . Thus, two manipulations that sensitize mice to the lethal effect of T cell-targeted polyclonal stimuli, withdrawal of endogenous GC, and injection of GAIN, per se induce apoptosis in peripheral T cells. Whether a massive apoptotic decay of lymphocytes contributes to the lethal effect of polyclonal stimuli, however, remains to be elucidated. In this context, it appears intriguing that the immunomodulator linomide, a substance that displays a marked antiapoptotic effect on peripheral T lymphocytes, also counteracts the lethal effect of bacterial endotoxins and exotoxins in vivo (Gonzalo, J. A., A. Gonz~lez-Garch, T. Kalland, G. Hedlund, C. Martfnez-A., and G. Kroemer, manuscript submitted for publication).
Concluding Remarks. As shown in this article, endogenous GC are involved in the regulation of the cellularity of lymphoid organs, programmed cell death of peripheral T cells, and specific superantigen responses. Mice treated with RU-38486 become susceptible to the fatal effect of T cell-targeted stimuli, anti-CD3e, and superantigen, i.e., substances that are not lethal per se and act via the stimulation of lymphokine release in T cells (22, 24, 25) . It has been shown previously that adrenalectomy enhances the mortality provoked by injection of other agents mimicking septic shock, namely LPS, TNF, and IL-1 (37) . Like SEB (Fig. 2) , LPS, IL-1, and TNF are potent inducers of GC in vivo (1, 38) . Thus, GC produced during acute immune stimulation may constitute an important feedback mechanism for contending the potentially lethal hyperactivation of the immune system. Accordingly, the presence of RU-38486 early after SEB injection, when endogenous GC rise over baseline levels, will have fatal consequences and interfere with the SEB/GCdriven reduction of VB8 + T cells. If these data were to be extrapolated to the human system, the treatment of persons at risk of sepsis with the antiglucocorticoid RU-38486 should be avoided.
A further potentially important observation concerns the kinetics with which exogenous GC will exert beneficial effects in this model of septic shock. To prevent acute death, GC have to be applied early after providing a polyclonal stimulus, i.e., within a few hours, thus mimicking the kinetics of endogenous GC elevation. This may be related to the fact that some critical events occur early after stimulation, e.g., the massive, GC-inhibitable secretion of TNF (22, 24) , and might explain why patients with established septic shock will scarcely profit from (late) GC medication (39) .
